Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Diabetes type 2 - Evidence
References

All references with links to [Free Full-text] are freely available online to users in the UK. Links to PubMed abstracts are also provided where available. CKS is not responsible for the content of external sites.

Free Full-text links are to dynamic documents that may have been updated since they were originally cited in the CKS topic. All links are checked regularly by CKS Information Specialists and updated to the latest version. Changes in the content of updated documents will not be reflected in the CKS topic text until the next revision.

The following references were cited in October 2009. References dated after this reflect new evidence incorporated since original publication of this topic.

  1. ABPI Medicines Compendium (2005) Summary of product characteristics for Glucophage. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  2. ABPI Medicines Compendium (2007a) Summary of product characteristics for Tritace tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  3. ABPI Medicines Compendium (2007b) Summary of product characteristics for Lipantil Micro 200. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  4. ABPI Medicines Compendium (2007c) Summary of product characteristics for Lopid 300mg capsules & 600mg film-coated tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  5. ABPI Medicines Compendium (2007d) Summary of product characteristics for Supralip 160mg. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  6. ABPI Medicines Compendium (2007e) Summary of product characteristics for Actos tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  7. ABPI Medicines Compendium (2007f) Summary of product characteristics for Plavix (sanofi-aventis Bristol-Myers Squibb SNC). Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  8. ABPI Medicines Compendium (2007g) Summary of product characteristics for Lipostat 10mg, 20mg and 40mg tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  9. ABPI Medicines Compendium (2007h) Summary of product characteristics for Istin. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  10. ABPI Medicines Compendium (2007i) Summary of product characteristics for Modalim tablets 100mg. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  11. ABPI Medicines Compendium (2008a) Summary of product characteristics for Floxapen capsules 500mg. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  12. ABPI Medicines Compendium (2008b) Summary of product characteristics for Bezalip Mono (Actavis UK). Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  13. ABPI Medicines Compendium (2008c) Summary of product characteristics for Byetta 5 micrograms solution for injection, prefilled pen. Byetta 10 micrograms solution for injection, prefilled pen. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  14. ABPI Medicines Compendium (2008d) Summary of product characteristics for Ezetrol 10mg tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  15. ABPI Medicines Compendium (2008e) Summary of product characteristics for Zestril 2.5mg, 5mg, 10mg, and 20mg tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  16. ABPI Medicines Compendium (2008f) Summary of product characteristics for Capoten tablets 12.5mg, 25mg, 50mg. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  17. ABPI Medicines Compendium (2008g) Summary of product characteristics for Adalat LA 30. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  18. ABPI Medicines Compendium (2008h) Summary of product characteristics for Galvus 50mg tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  19. ABPI Medicines Compendium (2008i) Summary of product characteristics for Avandia 4mg & 8mg film-coated tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  20. ABPI Medicines Compendium (2009a) Summary of product characteristics for Efient 5mg & 10mg film coated tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  21. ABPI Medicines Compendium (2009b) Summary of product characteristics for Angettes 75. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  22. ABPI Medicines Compendium (2009c) Summary of product characteristics for Januvia 100mg film-coated tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  23. ABPI Medicines Compendium (2009d) Summary of product characteristics for Zocor 10mg, 20mg, 40mg and 80mg film-coated tablets. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  24. ABPI Medicines Compendium (2009e) Summary of product characteristics for Victoza 6 mg/ml solution for injection in pre-filled pen. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  25. ABPI Medicines Compendium (2009f) Summary of product characteristics for Versatis 5% medicated plaster. Electronic Medicines Compendium. Datapharm Communications Ltd. www.emc.medicines.org.uk [Free Full-text]
  26. ACE Inhibitors in Diabetic Nephropathy Trialist Group (2001) Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Annals of Internal Medicine 134(5), 370-379. [Abstract] [Free Full-text]
  27. Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. New England Journal of Medicine 358(24), 2545-2559. [Abstract] [Free Full-text]
  28. ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine 358(24), 2560-2572. [Abstract] [Free Full-text]
  29. ALLHAT Officers (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of the American Medical Association 288(23), 2981-2997. [Abstract] [Free Full-text]
  30. American Diabetes Association (2006) Standards of medical care in diabetes - 2006. Diabetes Care 29(Suppl 1), S4-S42. [Free Full-text]
  31. American Diabetes Association (2008) Diagnosis and classification of diabetes mellitus. Diabetes Care 31(Suppl 1), S55-S60. [Free Full-text]
  32. Amiel, S.A., Dixon, T., Mann, R. and Jameson, K. (2008) Hypoglycaemia in type 2 diabetes. Diabetic Medicine 25(3), 245-254. [Abstract] [Free Full-text]
  33. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and death in high risk patients. British Medical Journal 324(7329), 71-86. [Abstract] [Free Full-text]
  34. Apelqvist, J., Bakker, K., van Houtum, W.H. et al. (2000) International consensus and practical guidelines on the management and the prevention of the diabetic foot. Diabetes/Metabolism Research and Reviews 16(Suppl 1), S84-S92. [Abstract]
  35. Ara, R., Tumur, I., Pandor, A. et al. (2008) Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. Health Technology Assessment 12(21), 1-212. [Abstract] [Free Full-text]
  36. Aronson, J.K. (Ed.) (2006) Meyler's side effects of drugs. The international encyclopedia of adverse drug reactions and interactions. Volume 3: E-I. 15th edn. Amsterdam: Elsevier.
  37. Ashley, C. and Currie, A. (Eds.) (2004) The renal drug handbook. 2nd edn. Abingdon, UK: Radcliffe Medical Press Ltd.
  38. Association of Clinical Biochemists (2009) HbA1c standardisation for clinical health care professionals. NHS Diabetes. www.diabetes.nhs.uk [Free Full-text]
  39. Baker, N., Murali-Krishnan, S. and Rayman, G. (2005a) A user's guide to foot screening. Part 3: skin and joints. Diabetic Foot 8(4).
  40. Baker, N., Murali-Krishnan, S. and Rayman, G. (2005b) A user's guide to foot screening. Part I: peripheral neuropathy. Diabetic Foot 8(1).
  41. Baker, N, Murali-Krishnan, S. and Fowler, D. (2005c) A user's guide to foot screening. Part 2: peripheral arterial disease. Diabetic Foot 8(2).
  42. Bar, S.L., Holmes, D.T. and Frohlich, J. (2007) Asymptomatic hypothyroidism and statin-induced myopathy. Canadian Family Physician 53(3), 428-431. [Free Full-text]
  43. Barnett, A.H., Bain, S.C., Bouter, P. et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New England Journal of Medicine 351(19), 1952-1961. [Abstract] [Free Full-text]
  44. Baxter, K. (Ed.) (2008) Stockley's drug interactions: a source book of interactions, their mechanisms, clinical importance and management. 8th edn. London: Pharmaceutical Press.
  45. Bazzano, L.A., Lee, L.J., Shi, L. et al. (2008) Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetic Medicine 25(8), 924-932. [Abstract]
  46. Belch, J., MacCuish, A., Campbell, I. et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. British Medical Journal 337, a1840. [Abstract] [Free Full-text]
  47. Bergenstal, R., Lewin, A., Bailey, T. et al. (2009) Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. Current Medical Research and Opinion 25(1), 65-75. [Abstract]
  48. Bhatt, D.L., Fox, K.A., Hacke, W. et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. New England Journal of Medicine 354(16), 1706-1717. [Abstract] [Free Full-text]
  49. Birjmohun, R.S., Hutten, B.A., Kastelein, J.J. and Stroes, E.S. (2005) Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. Journal of the American College of Cardiology 45(2), 185-197. [Abstract] [Free Full-text]
  50. Black, C., Donelly, P., McIntyre, L. et al. (2007) Meglitinide analogues for type 2 diabetes mellitus (Cochrane Review). The Cochrane Library. Issue 2. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  51. Blonde, L., Dailey, G.E., Jabbour, S.A. et al. (2004) Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Current Medical Research and Opinion 20(4), 565-572. [Abstract]
  52. Blonde, L., Dagogo-Jack, S., Banerji, M.A. et al. (2009) Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial - a primary care, type 2 diabetes study. Diabetes, Obesity and Metabolism 11(10), 978-986. [Abstract]
  53. Blood Pressure Lowering Treatment Trialists' Collaboration (2005) Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Archives of Internal Medicine 165(12), 1410-1419. [Abstract] [Free Full-text]
  54. BMA (2004) Diabetes mellitus: an update for health care professionals. British Medical Association. www.bma.org.uk [Free Full-text]
  55. BMA and NHS Employers (2009a) QOF changes and new indicators for 2009/10. British Medical Association. www.bma.org.uk [Free Full-text]
  56. BMA and NHS Employers (2009b) Quality and outcomes framework guidance for GMS contract 2009/10. British Medical Association and NHS Employers. www.nhsemployers.org [Free Full-text]
  57. BNF 56 (2008) British National Formulary. 56th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
  58. BNF 57 (2009) British National Formulary. 57th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain.
  59. Bolli, G., Dotta, F., Colin, L. et al. (2009) Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obesity and Metabolism 11(6), 589-595. [Abstract]
  60. Brenner, B.M., Cooper, M.E., De Zeeuw, D. et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 345(12), 861-869. [Abstract] [Free Full-text]
  61. British Cardiac Society, British Hypertension Society, Diabetes UK et al. (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91(Suppl 5), v1-v52. [Free Full-text]
  62. Brown, J.B., Pedula, K., Barzilay, J. et al. (1998) Lactic acidosis rates in type 2 diabetes. Diabetes Care 21(10), 1659-1663. [Abstract] [Free Full-text]
  63. BTA, ACB and BTF (2006) UK guidelines for the use of thyroid function tests. Association for Clinical Biochemistry, British Thyroid Association, British Thyroid Foundation. www.acb.org.uk [Free Full-text]
  64. Buse, J.B., Henry, R.R., Han, J. et al. (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylourea-treated patients with type 2 diabetes. Diabetes Care 27(11), 2628-2635. [Abstract] [Free Full-text]
  65. Buse, J.B., Rosenstock, J., Sesti, G. et al. (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational open-label trial (LEAD-6). Lancet 374(9683), 39-47. [Abstract]
  66. Camilleri, M. (2007) Diabetic gastroparesis. New England Journal of Medicine 356(8), 820-829.
  67. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348(9038), 1329-1339. [Abstract]
  68. Casas, J.P., Chua, W., Loukogeorgakis, S. et al. (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366(9502), 2026-2033. [Abstract]
  69. Cheng, A.Y.Y. and Fantus, I.G. (2005) Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian Medical Association Journal 172(2), 213-226. [Abstract] [Free Full-text]
  70. Chong, P.H. (2002) Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors. Annals of Pharmacotherapy 36(12), 1907-1917. [Abstract]
  71. Clar, C., Royle, P. and Waugh, N. (2009) Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One 4(7), e6112. [Abstract] [Free Full-text]
  72. Cobitz, A., Zambanini, A., Sowell, M. et al. (2008) A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14, 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiology and Drug Safety 17(8), 769-781. [Abstract]
  73. Cohn, J.N., Ziesche, S., Smith, R. et al. (1997) Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Circulation 96(3), 856-863. [Abstract] [Free Full-text]
  74. Cooper, A., Skinner, J., Nherera, L. et al. (2007) Clinical guidelines and evidence review for post myocardial infarction: secondary prevention in primary care and secondary care for patients following a myocardial infarction (full NICE guideline). National Collaborating Centre for Primary Care and Royal College of General Practitioners. www.nice.org.uk [Free Full-text]
  75. Cryer, P.E., Davis, S.N. and Shamoon, H. (2003) Hypoglycemia in diabetes. Diabetes Care 26(6), 1902-1912. [Abstract] [Free Full-text]
  76. CSM (1997) Drug interactions with grapefruit juice. Current Problems in Pharmacovigilance 23(Feb), 2. [Free Full-text]
  77. CSM (2002) Non-steroidal anti-inflammatory drugs (NSAIDs) and gastrointestinal (GI) safety. Current Problems in Pharmacovigilance 28(Apr), 5. [Free Full-text]
  78. CSM (2003) Reminder: gastrointestinal toxicity and NSAIDs. Current Problems in Pharmacovigilance 29(Sep), 8-9. [Free Full-text]
  79. CSM (2004a) Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 30(Oct), 1-2. [Free Full-text]
  80. CSM (2004b) Reminder: flucloxacillin and serious hepatic disorders. Current Problems in Pharmacovigilance 30(Oct), 9. [Free Full-text]
  81. Dahlöf, B., Sever, P.S., Poulter, N.R. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906. [Abstract]
  82. Deakin, T., McShane, C.E., Cade, J.E. and Williams, R.D.R.R. (2005) Group based training for self-management strategies in people with type 2 diabetes mellitus (Cochrane Review). The Cochrane Library. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  83. De Berardis, G., Sacco, M., Strippoli, G.F. et al. (2009) Asprin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 339(Nov 6), b4596. [Abstract] [Free Full-text]
  84. DeFronzo, R.A., Ratner, R.E., Han, J., et al. (2005) Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5), 1092-1100. [Abstract] [Free Full-text]
  85. de Jager, J., Kooy, A., Lehert, P. et al. (2010) Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 340, c2181.
  86. Diabetes UK (2000) Care recommendations: new diagnostic criteria for diabetes. Diabetes UK. www.diabetes.org.uk [Free Full-text]
  87. Diabetes UK (2004) Weight management. Managing diabetes in primary care. Diabetes UK. www.diabetes.org.uk [Free Full-text]
  88. Diamond, G.A., Bax, L. and Kaul, S. (2007) Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 147(8), 578-581. [Abstract] [Free Full-text]
  89. Diener, H.C., Bogousslavsky, J., Brass, L. et al. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431), 331-337. [Abstract]
  90. Dormandy, J.A., Charbonnel, B., Eckland, D.J. et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366(9493), 1279-1289. [Abstract]
  91. DTB (2002) Managing foot ulcers in patients with diabetes. Drug & Therapeutics Bulletin 40(2), 11-14. [Abstract]
  92. DTB (2007) Self-monitoring of blood glucose in diabetes. Drug & Therapeutics Bulletin 45(9), 65-70. [Abstract]
  93. DTB (2008a) Glitazones in type 2 diabetes: an update. Drug & Therapeutics Bulletin 46(4), 25-29. [Abstract]
  94. DTB (2008b) Three new drugs for type 2 diabetes. Drug & Therapeutics Bulletin 46(7), 49-52. [Abstract]
  95. DVLA (2010) At a glance guide to the current medical standards of fitness to drive (August update). Driver and Vehicle Licensing Agency. www.dvla.gov.uk [Free Full-text]
  96. Edmonds, M. (2006) Diabetic foot ulcers: practical treatment recommendations. Drugs 66(7), 913-929. [Abstract]
  97. Edmonds, M.E. and Foster, A.V.M. (2006) Diabetic foot ulcers. British Medical Journal 332(7538), 407-410. [Free Full-text]
  98. Eisenberg, M.J., Brox, A. and Bestawros, A.N. (2004) Calcium channel blockers: an update. American Journal of Medicine 116(1), 35-43. [Abstract]
  99. EMEA (2009) Press release: European Medicines Agency update on safety of insulin glargine (23rd July 2009). European Medicines Agency. www.emea.europa.eu [Free Full-text]
  100. Fagot-Campagna, A., Narayan, K.M. and Imperatore, G. (2001) Type 2 diabetes in children. British Medical Journal 322(7283), 377-378. [Free Full-text]
  101. Fakhoury, W., Lockhart, I., Kotchie, R.W. et al. (2008) Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. Pharmacology 82(2), 156-163. [Abstract]
  102. Farmer, A., Wade, A., Goyder, E. et al. (2007) Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. British Medical Journal 335(7611), 132. [Abstract] [Free Full-text]
  103. Ferrannini, E., Fonseca, V., Zinman, B. et al. (2009) Fifty-two-week efficacy and safety of vildagliptin vs glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obesity and Metabolism 11(2), 157-166. [Abstract]
  104. FFPRHC (2005) FFPRHC guidance (April 2005): drug interactions with hormonal contraception. Journal of Family Planning and Reproductive Health Care 31(2), 139-151. [Free Full-text]
  105. FFPRHC (2007) First prescription of combined oral contraception. Faculty of Sexual & Reproductive Healthcare. www.ffprhc.org.uk [Free Full-text]
  106. Frykberg, R.G., Armstrong, D.G., Giurini, J. et al. (2000) Diabetic foot disorders. A clinical practice guideline. Journal of Foot & Ankle Surgery 39(Suppl 5), S1-S60. [Abstract]
  107. Fujioka, K., Pans, M. and Joyal, S. (2003) Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended release formulation. Clinical Therapeutics 25(2), 515-529. [Abstract]
  108. Fujioka, K., Brazg, R.L., Raz, I. et al. (2005) Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes, Obesity and Metabolism 7(1), 28-39. [Abstract]
  109. Gao, Y., Yoon, K.H., Chuang, L.M. et al. (2009) Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Research and Clinical Practice 83(1), 69-76. [Abstract]
  110. Garber, A.J., Foley, J.E., Banerji, M.A. et al. (2008) Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obesity and Metabolism 10(11), 1047-1056. [Abstract]
  111. Gerstein, H.C. and Haynes, R.B. (Eds.) (2001) Evidence-based diabetes care. London: BC Decker.
  112. Glasziou, P.P., Irwig, L., Heritier, S. et al. (2008) Monitoring cholesterol levels: measurement error or true change? Annals of Internal Medicine 148(9), 656-661. [Abstract] [Free Full-text]
  113. Goke, B., Hershon, K., Kerr, D. et al. (2008) Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Hormone and Metabolic Research 40(12), 892-895. [Abstract]
  114. Goldstein, D.J., Lu, Y., Detke, M.J. et al. (2005) Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116(1-2), 109-118. [Abstract]
  115. Graham, D.J., Ouellet-Hellstrom, R., MaCurdy, T.E. et al. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304(4), 411-418. [Abstract]
  116. Haffner, S.M., Lehto, S., Ronnemaa, T. et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with or without prior myocardial infarction. New England Journal of Medicine 339(4), 229-234. [Abstract] [Free Full-text]
  117. Hawkey, C.J. and Lanas, A.I. (2001) Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement. American Journal of Medicine 110(1A), 79S-100S.
  118. Hayden, M., Pignone, M., Phillips, C. and Mulrow, C. (2002) Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 136(2), 161-172. [Abstract] [Free Full-text]
  119. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355(9200), 253-259. [Abstract]
  120. Heart Protection Study Collaborative Group (2002) MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22. [Abstract]
  121. Holman, R.R., Paul, S.K., Bethel, M.A. et al. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine 359(15), 1577-1589. [Abstract] [Free Full-text]
  122. Holt, T. and Kumar, S. (2010a) Diagnosing Diabetes. In: Holt, T. and Kumar, S. (Eds.) ABC of Diabetes. 6 edn. : Wiley-Blackwell Publication, BMJ Books.. 1-4.
  123. Holt, T. and Kumar, S. (2010b) Types of Diabetes. In: Holt, T. and Kumar, S. (Eds.) ABC of Diabetes. 6 edn. : Wiley-Blackwell Publication, BMJ Books.. 5-8.
  124. Home, P.D., Pocock.S.J., Beck-Nielsen, H. et al. (2007) Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. New England Journal of Medicine 357(1), 28-38. [Abstract] [Free Full-text]
  125. HPA and Association of Medical Microbiologists (2008) Management of infection guidance for primary care for consultation and local adaptation. Health Protection Agency. www.hpa.org.uk [Free Full-text]
  126. Hu, F.B., Manson, J.E., Stampfer, M.J. et al. (2001) Diet, lifestyle and the risk of type 2 diabetes mellitus in women. New England Journal of Medicine 345(11), 790-797. [Abstract] [Free Full-text]
  127. Hundal, R.S. and Inzucchi, S.E. (2003) Metformin: new understandings, new uses. Drugs 63(18), 1879-1894. [Abstract]
  128. Intercollegiate Stroke Working Party (2008) National clinical guideline for stroke: third edition. Royal College of Physicians. www.rcplondon.ac.uk [Free Full-text]
  129. Inzucchi, S.E. (2002) Oral antihyperglycemic therapy for type 2 diabetes: scientific review. Journal of the American Medical Association 287(3), 360-372. [Abstract] [Free Full-text]
  130. Jansen, J.P. (2006) Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Current Medical Research and Opinion 22(4), 671-681. [Abstract]
  131. Joint Specialty Committee on Renal Medicine of the Royal College of Physicians and Renal Association (2006) Chronic kidney disease in adults: UK guidelines for identification, management and referral. Royal College of Physicians. www.renal.org [Free Full-text]
  132. Jones, G.C., Macklin, J.P. and Alexander, W.D. (2003) Contraindications to the use of metformin. British Medical Journal 326(7379), 4-5. [Free Full-text]
  133. Kahn, S.E., Haffner, S.M., Heise, M.A. et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355(23), 2427-2443. [Abstract] [Free Full-text]
  134. Kendall, D.M., Riddle, M.C., Rosenstock, J. et al. (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28(5), 1083-1091. [Abstract] [Free Full-text]
  135. Khunti, K., Stone, M.A., Burden, A.C. et al. (2006) Randomised controlled trial of near-patient testing for glycated haemoglobin in people with type 2 diabetes mellitus. British Journal of General Practice 56(528), 511-517. [Abstract] [Free Full-text]
  136. Kshirsagar, A.V., Joy, M.S., Hogan, S.L. et al. (2000) Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases 35(4), 695-707. [Abstract]
  137. Kumar, S. and Hall, R.J. (2003) Drug treatment of stable angina pectoris in the elderly: defining the place of calcium channel antagonists. Drugs & Aging 20(11), 805-815. [Abstract]
  138. Lago, R.M., Singh, P.P. and Nesto, R.W. (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidediones: a meta-analysis of randomised clinical trials. Lancet 370(9593), 1129-1136. [Abstract]
  139. Law, M. and Rudnicka, A.R. (2006) Statin safety: a systematic review. American Journal of Cardiology 97(8A), 52C-60C. [Abstract]
  140. Law, M.R., Wald, N.J., Morris, J.K. and Jordan, R.E. (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. British Medical Journal 326(7404), 1427-1434. [Abstract] [Free Full-text]
  141. Leese, G.P., Reid, F., Green, V. et al. (2006) Stratification of foot ulcer risk in patients with diabetes: a population-based study. International Journal of Clinical Practice 60(5), 541-545. [Abstract]
  142. Lewis, E.J., Hunsicker, L.G., Clarke, W.R. et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 345(12), 851-860. [Abstract] [Free Full-text]
  143. Lincoff, A.M., Wolski, K., Nicholls, S.J. and Nissen, S.E. (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Journal of the American Medical Association 298(10), 1180-1188. [Abstract] [Free Full-text]
  144. Littler, W.A. and Sheridan, D.J. (1995) Placebo controlled trial of felodipine in patients with mild to moderate heart failure. British Heart Journal 73(5), 428-433. [Abstract] [Free Full-text]
  145. Loke, Y.K., Singh, S. and Furberg, C.D. (2009) Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. Canadian Medical Association Journal 180(1), 32-39. [Abstract] [Free Full-text]
  146. London and South East Medicines Information Service, South West Medicines Information Service and Croydon Primary Care Trust (2008) Suggestions for drug monitoring in adults in primary care. National Electronic Library for Medicines. www.nelm.nhs.uk [Free Full-text]
  147. Mannucci, E., Monami, M., Di Bari, M. et al. (2009) Cardiac safety profile of rosiglitazone A comprehensive meta-analysis of randomized clinical trials. International Journal of Cardiology epub ahead of print. [Abstract]
  148. Marre, M, Lievre, M, Chatellier, G et al. (2004) Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). British Medical Journal 328(7438), 495. [Abstract] [Free Full-text]
  149. McIntosh, A., Peters, J., Young, R. et al. (2003) Prevention and management of foot problems in type 2 diabetes: clinical guidelines and evidence (full NICE guideline). National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  150. McKenney, J.M., Davidson, M.H., Jacobson, T.A. et al. (2006) Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. American Journal of Cardiology 97(8A), 89C-94C. [Abstract]
  151. MeReC (2004) Drug management of type 2 diabetes: summary. MeReC Bulletin 15(1). [Free Full-text]
  152. MeReC (2007) Update on the CV risk of glitazones. MeReC Extra 30(Nov), 7. [Free Full-text]
  153. MHRA (2007a) Fibrates: new prescribing advance. Drug Safety Update 1(4), 2-3. [Free Full-text]
  154. MHRA (2007b) Rosiglitazone and pioglitazone: cardiovascular safety. Drug Safety Update 1(5), 5-6. [Free Full-text]
  155. MHRA (2007c) ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy. Drug Safety Update 1(5), 8-9. [Free Full-text]
  156. MHRA (2008a) Statins: interactions and updated advice for atorvastatin. Drug Safety Update 1(6), 2-4. [Free Full-text]
  157. MHRA (2008b) Statins: class effects identified. Drug Safety Update 1(7), 2. [Free Full-text]
  158. MHRA (2008c) Ezetimibe and results of SEAS study: possible increased risk of cancer. Drug Safety Update 2(4), 7. [Free Full-text]
  159. MHRA (2009a) ACE inhibitors and angiotensin II receptor antagonists: recommendations on use during breastfeeding. Drug Safety Update 2(10), 3-4. [Free Full-text]
  160. MHRA (2009b) Clarification: ACE inhibitors and angiotensin II receptor antagonists: use during breastfeeding. Drug Safety Update 2(12), 10. [Free Full-text]
  161. MHRA (2009c) Exenatide (Byetta): risk of severe pancreatitis and renal failure. Drug Safety Update 8(2), 6-7. [Free Full-text]
  162. MHRA (2009d) Insulin glargine: studies of possible cancer link. Drug Safety Update 3(2), 3-4. [Free Full-text]
  163. MHRA (2009e) Aspirin: not licensed for primary prevention of thrombotic vascular disease. Drug Safety Update 3(3), 10-11. [Free Full-text]
  164. MHRA (2010a) Current advice and information about the use of rosiglitazone (Avandia, Avandamet black triangle) in the treatment of diabetes. Medicines and Healthcare products Regulatory Agency. www.mhra.gov.uk [Free Full-text]
  165. MHRA (2010b) Rosiglitazone (Avandia, Avandamet): Recommended withdrawal from clinical use. Medicines and Healthcare products Regulatory Agency. www.mhra.gov.uk [Free Full-text]
  166. Micromedex (2006) MICROMEDEX [CD-ROM]. (vol 127, 1st quarter 2006). Thomson Healthcare.
  167. Micromedex (2009) MICROMEDEX [CD-ROM]. (Vol 140, 2nd quarter 2009). Thomson Healthcare.
  168. Mogensen, C.E., Neldam, S., Tikkanen, I. et al. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. British Medical Journal 321(7274), 1440-1444. [Abstract] [Free Full-text]
  169. Monami, M., Lamanna, C., Marchionni, N. and Mannucci, E. (2008a) Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 31(7), 1455-1460. [Abstract] [Free Full-text]
  170. Monami, M., Marchionni, N. and Mannucci, E. (2008b) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Research and Clinical Practice 81(2), 184-189. [Abstract]
  171. Nagajothi, N., Adigopula, S., Balamuthusamy, S. et al. (2008) Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. American Journal of Therapeutics 15(6), 506-511. [Abstract]
  172. Nair, R.K., Karadi, R.L. and Kilpatrick, E.S. (2008) Managing patients with 'statin intolerance': a retrospective study. British Journal of Cardiology 15(3), 158-160. [Free Full-text]
  173. Nathan, D.M., Buse, J.B., Davidson, M.B. et al. (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8), 1963-1972. [Free Full-text]
  174. National Collaborating Centre for Chronic Conditions (2006) Hypertension. Management of hypertension in adults in primary care: pharmacological update (full NICE guideline). CG034 and update of NICE clinical guideline 18. Royal College of Physicians and British Hypertension Society. www.nice.org.uk [Free Full-text]
  175. National Collaborating Centre for Chronic Conditions (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care: update (full NICE guideline). National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  176. National Collaborating Centre for Primary Care (2008) Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (full NICE guideline). Royal College of General Practitioners. www.nice.org.uk [Free Full-text]
  177. National Diabetes Support Team (2006) Diabetes in black and minority ethnic communities. NHS Clinical Governance Support Team. www.diabetes.nhs.uk [Free Full-text]
  178. Newman, D.J., Mattock, M.B., Dawnay, A.B.S. et al. (2005) Systematic review on urine albumin testing for early detection of diabetic complications. Health Technology Assessment 9(30), 1-180. [Free Full-text]
  179. NHS Diabetes (2010) Self monitoring of blood glucose in non-insulin-treated Type 2 diabetes: a report prepared by an NHS Diabetes Working Group (Mar 2010). NHS Diabetes. www.diabetes.nhs.uk [Free Full-text]
  180. NICE (2002) Management of type 2 diabetes: management of blood pressure and blood lipids (NICE guideline). Inherited clinical guideline H. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  181. NICE (2003) Clinical effectiveness and cost effectiveness of glitazones for the treatment of type 2 diabetes. Final appraisal determination. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  182. NICE (2004) Type 2 diabetes: prevention and management of foot problems (NICE guideline). Clinical guideline 10. National Institute for Health and Clinical Exellence. www.nice.org.uk [Free Full-text]
  183. NICE (2006) Statins for the prevention of cardiovascular events. Technology appraisal 94. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  184. NICE (2007) Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. NICE technology appraisal guidance 132. National Institute for Health and Clinical Evidence. www.nice.org.uk [Free Full-text]
  185. NICE (2008a) Type 2 diabetes: the management of type 2 diabetes (NICE guideline). National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  186. NICE (2008b) Lipid modification: cardiovascular risk assessment for the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (NICE guideline). National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  187. NICE (2009a) Type 2 diabetes: the management of type 2 diabetes - update. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  188. NICE (2009b) Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  189. NICE (2010a) Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  190. NICE (2010b) Neuropathic pain - pharmacological management: draft guideline consultation - stakeholder comments and responses. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  191. NICE (2010c) Type 2 diabetes - newer agents (a partial update of CG66): NICE guideline. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  192. NICE (2010d) Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings [NICE statement - July 2010]. National Institute for Health and Clinical Excellence. www.nice.org.uk [Free Full-text]
  193. Nissen, S.E. and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356(24), 2457-2471. [Abstract] [Free Full-text]
  194. Nissen, S.E. and Wolski, K. (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Archives of Internal Medicine epub ahead of print. [Abstract]
  195. North West Podiatry Services (2008) Guidelines for the prevention and management of foot problems for people with diabetes. North West Podiatry Services. www.library.nhs.uk [Free Full-text]
  196. NZGG (2003) Appendix F. Use of a 10 gram monofilament. Management of type 2 diabetes. New Zealand Guidelines Group. www.nzgg.org.nz [Free Full-text]
  197. Ogawa, H., Nakayama, M. and Morimoto, T. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. Journal of the American Medical Association 300(18), 2134-2141. [Abstract] [Free Full-text]
  198. O'Kane, M., Bunting, B. and Copeland, M. (2008) Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. British Medical Journal 336(7654), 1174-1177. [Abstract] [Free Full-text]
  199. Packer, M., O'Connor, C.M., Ghali, J.K. et al. (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. New England Journal of Medicine 335(15), 1107-1114. [Abstract] [Free Full-text]
  200. Parving, H.H., Lehnert, H., Brochner-Mortensen, J. et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 345(12), 870-878. [Abstract] [Free Full-text]
  201. Pham, H., Armstrong, D.G., Harvey, C. et al. (2000) Screening techniques to identify people at high risk for diabetic foot ulceration: a prospective multicenter trial. Diabetes Care 23(5), 606-611. [Abstract] [Free Full-text]
  202. Pinelli, N.R., Cha, R., Brown, M.B. and Jaber, L.A. (2008) Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Annals of Pharmacotherapy 42(11), 1541-1551. [Abstract]
  203. Raskin, J., Pritchett, Y.L., Wang, F. et al. (2005) A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Medicine 6(5), 346-356. [Abstract]
  204. Rendell, M. (2004) The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64(12), 1339-1358. [Abstract]
  205. Richter, B., Bandeira-Echtler, E., Bergerhoff, K. et al. (2006) Pioglitazone for type 2 diabetes mellitus (Cochrane Review). The Cochrane Library. Issue 4. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  206. Richter, B., Bandeira-Echtler, E., Bergerhoff, K. and Lerch, C. (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus (Cochrane Review). The Cochrane Library. Issue 2. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  207. Rosenstock, J., Niggli, M. and Maldonado-Lutomirsky, M. (2009) Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 11(6), 571-578. [Abstract]
  208. Saarto, T. and Wiffen, P.J. (2007) Antidepressants for neuropathic pain (Cochrane Review). The Cochrane Library. Issue 4. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  209. Sacco, M., Pellegrini, F., Roncaglioni, M.C. et al. (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26(12), 3264-3272. [Abstract] [Free Full-text]
  210. Saenz, A., Fernandez-Esteban, I., Mataix, A. et al. (2005) Metformin monotherapy for type 2 diabetes (Cochrane Review). The Cochrane Library. Issue 3. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  211. Salpeter, S., Greyber, E., Pasternak, G. and Salpeter, E. (2006) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus (Cochrane Review). The Cochrane Library. Issue 1. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  212. Sarol, J.N., Nicodemus, N.A., Tan, K.M. and Grava, M.B. (2005) Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Current Medical Research and Opinion 21(2), 173-184. [Abstract]
  213. Schaefer, C., Peters, P. and Miller, R.K. (Eds.) (2007) Drugs during pregnancy and lactation: treatment options and risk assessment. 2nd edn. Oxford: Academic Press.
  214. Scherbaum, W.A., Schweizer, A., Mari, A. et al. (2008) Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia*. Diabetes, Obesity & Metabolism 10(8), 675-682. [Abstract]
  215. SIGN (2001) Management of diabetes: a national clinical guideline [Replaced by clinical guideline 116]. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk [Free Full-text]
  216. SIGN (2007) Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk [Free Full-text]
  217. SIGN (2010) Management of diabetes: a national clinical guideline. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk [Free Full-text]
  218. Simon, J., Gray, A., Clarke, P. et al. (2008) Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. British Medical Journal 336(7654), 1177-1180. [Abstract] [Free Full-text]
  219. Singh, S., Loke, Y.K. and Furberg, C.D. (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Journal of the American Medical Association 298(10), 1189-1195. [Abstract] [Free Full-text]
  220. Smellie, W.S. (2006) Testing pitfalls and summary of guidance in lipid management. British Medical Journal 333(7558), 83-86. [Free Full-text]
  221. Smellie, W.S.A., Wilson, D., McNulty, C.A.M. et al. (2005) Best practice in primary care pathology: review 1. Journal of Clinical Pathology 58(10), 1016-1024. [Abstract] [Free Full-text]
  222. Smellie, W.S., Forth, J., Coleman, J.J. et al. (2007) Best practice in primary care pathology: review 6. Journal of Clinical Pathology 60(3), 225-234. [Abstract] [Free Full-text]
  223. Song, S.H. and Brown, P.M. (2004) Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic Medicine 21(3), 238-245. [Abstract]
  224. Srinivasan, B., Taub, N., Khunti, K. and Davies, M. (2008) Diabetes: glycaemic control in type 2. Clinical Evidence. BMJ Publishing Ltd. www.clinicalevidence.com
  225. Stang, M., Wysowski, D.K. and Butler-Jones, D. (1999) Incidence of lactic acidosis in metformin users. Diabetes Care 22(6), 925-927. [Abstract] [Free Full-text]
  226. Strippoli, G.F., Craig, M. and Craig, J.C. (2005) Antihypertensive agents for preventing diabetic kidney disease (Cochrane Review). The Cochrane Library. Issue 4. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  227. Strippoli, G.F.M., Bonifati, C., Craig, M. et al. (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease (Cochrane Review). The Cochrane Library. Issue 4. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  228. Strom, B.L., Schinnar, R., Apter, A.J. et al. (2003) Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. New England Journal of Medicine 349(17), 1628-1635. [Abstract] [Free Full-text]
  229. Stumvoll, M., Goldstein, B.J. and van Haeften, T.W. (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365(9467), 1333-1346. [Abstract]
  230. Sweetman, S.C. (Ed.) (2005) Martindale: the complete drug reference. 34th edn. London: Pharmaceutical Press.
  231. Takeda UK Medical Adviser (2006) Personal communication. Medical Advisor, Takeda UK Ltd: High Wycombe, Buckinghamshire.
  232. Thackray, S., Witte, K., Clark, A.L. and Cleland, J.G. (2000) Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. European Journal of Heart Failure 2(2), 209-212. [Abstract]
  233. Thadani, U. (2004) Current medical management of chronic stable angina. Journal of Cardiovascular Pharmacology & Therapeutics 9(Suppl 1), S11-S29. [Abstract]
  234. UK Prospective Diabetes Study Group (1998a) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131), 854-865. [Abstract]
  235. UK Prospective Diabetes Study Group (1998b) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131), 837-853. [Abstract]
  236. UK Prospective Diabetes Study Group (1999) Glycemic control with diet, sulfonylurea, metformin and insulin therapy in patients with type 2 diabetes: progressive requirement for multiple therapies (UKPDS 49). Journal of the American Medical Association 281(21), 2005-2012. [Abstract] [Free Full-text]
  237. UK Prospective Diabetes Study Group, Stratton, I.M., Adler, A.I. et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321(7258), 405-412. [Abstract] [Free Full-text]
  238. Warrell, D.A., Cox, T.M. and Firth, J.D. (Eds.) (2003) Oxford textbook of medicine. Volume 2. 4th edn. New York: Oxford University Press.
  239. Welschen, L.M.C., Bloemendal, E., Nijpels, G. et al. (2005) Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin (Cochrane Review). The Cochrane Library. Issue 2. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  240. WeMeReC (2005) Type 2 diabetes: important aspects of care. WeMeReC. Welsh Medicines Resource Centre. www.wemerec.org [Free Full-text]
  241. WHO (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Geneva: World Health Organization. www.who.int [Free Full-text]
  242. WHO (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. World Health Organization. www.who.int [Free Full-text]
  243. Wiffen, P.J., McQuay, H.J., Edwards, J.E. and Moore, R.A. (2005) Gabapentin for acute and chronic pain (Cochrane review). The Cochrane Library. Issue 3. John Wiley & Sons, Ltd. www.thecochranelibrary.com [Free Full-text]
  244. Williams, G. (2003) Diabetes. In: Warrell, D.A., Cox, T.M., Firth, J.D. and Benz, E.J. (Eds.) Oxford textbook of medicine. Oxford: Oxford University Press. 317-360.
  245. Williams-Herman, D., Round, E., Swern, A.S. et al. (2008) Safety and tolerability of sitagliptin in patients with type 2 diabetes: A pooled analysis. BMC Endocrine Disorders 8(14). [Abstract] [Free Full-text]
  246. Zhang, C., Sun, A., Zhang, P. et al. (2010) Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Research & Clinical Practice 87(2), 211-218. [Abstract]

© NHS Institute for Innovation and Improvement